Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Solid Biosciences Inc SLDB

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3... see more

Recent & Breaking News (NDAQ:SLDB)

Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences

GlobeNewswire June 23, 2022

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality

GlobeNewswire June 2, 2022

Solid Biosciences to Participate at the Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Solid Biosciences to Present at ASGCT 25th Annual Meeting and CureDuchenne 2022 FUTURES National Conference

GlobeNewswire May 17, 2022

Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy

GlobeNewswire April 27, 2022

Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results

GlobeNewswire April 25, 2022

Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001

GlobeNewswire March 14, 2022

Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

GlobeNewswire February 10, 2022

Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates

GlobeNewswire January 10, 2022

Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2022

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources

GlobeNewswire January 4, 2022

Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results

GlobeNewswire November 3, 2021

Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development

GlobeNewswire November 2, 2021

Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit

GlobeNewswire October 21, 2021

Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

Business Wire October 4, 2021

Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

GlobeNewswire September 29, 2021

Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

GlobeNewswire September 23, 2021

Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

GlobeNewswire September 20, 2021

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire September 20, 2021

Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021

GlobeNewswire August 24, 2021